急性髓系白血病(acute myeloid leukemia,AML)是一种异质性髓系恶性肿瘤,目前化疗联合造血干细胞移植是主要治疗方法,但是总体预后较差.吉妥珠单抗(gemtuzumab ozogamicin,GO)是一种人源化抗CD33单抗与卡奇霉素结合的抗体偶联药物,主要用于治疗CD33阳性AML.虽然研究发现GO可以改善CD33阳性AML患者的预后,但是仍有部分AML患者并未获益.GO治疗AML的疗效主要与CD33表达及单核苷酸多态性(single nucleotide polymorphism,SNP)、ATP 结合盒亚家族B成员 1(ATP-binding cassette subfamily B member 1,ABCB1)基因及SNP、特异的分子生物学和细胞遗传学等因素有关.本文就GO对AML疗效影响因素的研究进展进行综述.
Research progress on factors influencing the therapeutic effect of gemtuzumab ozo-gamicin for acute myeloid leukemia
Acute myeloid leukemia(AML)is a heterogeneous myeloid malignancy.Currently,chemotherapy combined with hematopoietic stem cell transplantation is the primary treatment option;however,over-all prognosis remains poor.Gemtuzumab ozogamicin(GO)is a hu-manized CD33 monoclonal antibody conjugated with calicheamicins.It is primarily used to treat CD33-positive AML.Although studies have found that GO can improve the prognosis of patients with CD33-positive AML,some patients with AML do not benefit from it.Recent stud-ies have found that the effect of GO on AML is primarily associated with the expression of CD33 and its single nucleotide polymorphism(SNP),ATP-binding cassette subfamily B member 1(ABCB1)gene and SNP,as well as specific molecular biology and cytogenetics.This paper reviews the research progress on the factors influencing efficacy of GO for treating AML.
NETL
NSTL
万方数据
